After CE or NMPA, Is Australia the Natural Second Market?
A single-country Australian medical-device entry plan: appoint a local Sponsor, use qualifying CE or FDA evidence through TGA's OCA system, keep ARTG control and Sponsor-switch terms explicit, and separately screen the dated May 2026 NMPA / 41HD exception.
Regional verdict
Australia is a light Mode B market: every foreign manufacturer needs an Australian Sponsor, and that Sponsor holds the ARTG entry, but a defined Sponsor Change process takes about 2–4 months and allows the product to keep selling while the change is processed. CE has the strongest documented leverage: a current NANDO-listed Notified Body CE certificate can serve as OCA evidence and substitute for TGA's independent technical assessment for qualifying moderate- and high-risk devices. US FDA 510(k), De Novo, and PMA sit at the same OCA tier. Separately, the allowed sources report that from May 1, 2026 NMPA joined TGA's list of eight recognized reference regulators and can support a 41HD emergency-access application without CE or FDA; this is an industry-report flag checked on August 18, 2026, with the official text still awaiting direct verification.
Standard pathway flow
Use CE-backed OCA as the main route where eligible, but keep Sponsor appointment, Australian classification, evidence-scope matching, ARTG inclusion, and local maintenance as separate gates.
1. Appoint and contract the Australian Sponsor
The Sponsor must be an Australian registered entity or eligible individual, hold a TGA Business Services account, submit and maintain the ARTG application, pay annual charges, manage vigilance and recalls, and receive TGA communications. Lock technical-file ownership and Sponsor-change terms before filing.
2. Confirm Australian classification and the evidence route
Classify under the Australian rules rather than assuming an automatic foreign-class mapping. Then determine whether the device has qualifying CE or FDA OCA evidence, needs TGA proprietary conformity assessment, or should be screened against the separately flagged NMPA / 41HD exception.
3. Build the conformity-assessment evidence package
For OCA, provide the current overseas certificate, declaration or technical summary, scope-matched product information, QMS evidence, Australian label draft, and the manufacturer's authority to the Sponsor. Without OCA, the source page requires the full TGA technical and clinical package.
4. File through TGA Business Services and obtain ARTG inclusion
The Sponsor files the applicable listing or registration application. TGA checks completeness, evidence validity and scope, and Australian labelling; after successful inclusion, the product receives an ARTG number and may be lawfully supplied.
5. Maintain the ARTG entry and local obligations
Pay the annual ARTG charge, keep the underlying OCA certificate current, report adverse events and recalls, maintain post-market evidence, and notify or obtain prior approval for product changes according to their significance.
License-holder arrangements
Australia is Mode B because the ARTG entry sits with the local Sponsor, not the overseas manufacturer. It is lighter than many Asian Mode B markets because the country page documents a formal Sponsor Change process and continued sales during processing.
Sponsor as ARTG entry holder
The Sponsor submits and maintains the entry, pays annual charges, handles TGA communications, adverse-event reporting and recalls, and is the formal responsible party recorded in ARTG.
Manufacturer retains the technical file
The country page says the commercial agreement should place technical-data-package ownership with the manufacturer and define ARTG transfer, quality, recall-cost, and IP responsibilities.
Sponsor Change: defined but not instant
A Sponsor Change application needs TGA approval and takes about 2–4 months. The source page states that the product may continue to be sold while the change is processed.
The Sponsor controls the ARTG entry in operation, so transfer rights and data access must be contracted before filing even though the statutory switch mechanism is comparatively gentle.
Reference-certificate leverage
- Main route — CE-based OCA: a current CE certificate issued by a NANDO-listed Notified Body is formally accepted as OCA evidence. For qualifying moderate- and high-risk devices, it substitutes for TGA's independent technical assessment, while scope matching, Sponsor, classification, labelling, ARTG and post-market duties remain.
- FDA sits alongside CE: FDA 510(k), De Novo, and PMA are accepted at the same highest OCA tier. The Australian country page's OCA table also names Health Canada MDL and Japan PMDA for selected product categories.
- Dated NMPA exception — not historical OCA: the allowed sources report that TGA added NMPA to a list of eight recognized reference regulators on May 1, 2026 and allowed NMPA-certificate holders to apply through the 41HD emergency-access route without CE or FDA. The sources do not enumerate all eight regulators, and the official text remains pending direct verification.
- The 41HD report is flagged, not generalized: it was checked on August 18, 2026 as an industry report relaying an official action, with official source text queued for monthly re-verification. It does not establish general mutual recognition or waive Sponsor, Australian classification, labelling, or post-market duties.
Suggested entry sequence
After securing a qualifying Notified-Body CE certificate, appoint the Sponsor, independently confirm Australian classification and scope, and reuse the CE package through OCA. The country page describes Australia as one of the markets where CE carries the strongest leverage.
Before commissioning a separate CE or FDA route solely for Australia, screen the May 1, 2026 NMPA / 41HD exception. Keep it conditional because the available source is an industry report and the official text remains pending direct verification.
Country-by-country delta table
| Country | Regulator | Registration form | Licence holder mode | Validity | Key special requirement |
|---|---|---|---|---|---|
| Australia | TGA / ARTG | Sponsor-filed ARTG listing or inclusion; qualifying CE/FDA evidence can support OCA, otherwise TGA proprietary conformity assessment applies | Mode B — Australian Sponsor holds and maintains the ARTG entry; Sponsor Change takes about 2–4 months with continued sales during processing | No fixed ARTG expiry while annual charges are paid and compliance and underlying OCA evidence are maintained | Australian classification and scope matching; Sponsor information and ARTG number on local labelling; change notification or prior approval according to significance |
Common pitfalls
- Letting a weak Sponsor control the ARTG entry without transfer protections: the country page identifies Sponsor selection as the highest-frequency, highest-impact risk. Contract for technical-file ownership, ARTG transfer, annual-charge funding, recall responsibilities, and termination before filing.
- Assuming the foreign certificate scope automatically matches the ARTG application: TGA can suspend review where CE or FDA evidence does not fully cover the Australian models, intended use, or application scope.
- Missing change-notification duties: safety- or performance-affecting changes must be reported to TGA; major changes need prior approval, minor changes require notification, and significant design or indication changes can require a new or amended ARTG application.
Explore the country pages
Each row links to the full country regulatory report for registration pathway, timeline, cost, and post-market obligations.